Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
- 28 January 2011
- journal article
- review article
- Published by Elsevier BV in Cancer Letters
- Vol. 300 (2), 115-121
- https://doi.org/10.1016/j.canlet.2010.10.018
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.Blood, 2009
- Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemiaLeukemia, 2009
- Patient adherence and persistence with oral anticancer treatmentCA: A Cancer Journal for Clinicians, 2009
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood, 2006
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- Chronic Myeloid Leukemia — Advances in Biology and New Approaches to TreatmentNew England Journal of Medicine, 2003
- Molecular mechanisms of transformation by the BCR-ABL oncogeneSeminars in Hematology, 2003
- BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Blood, 2003
- Chronic Myelogenous Leukemia: Biology and TherapyAnnals of Internal Medicine, 1999